BRIUMVI
BRIUMVI (ublituximab) is a monoclonal antibody that binds to a molecule (CD20) on the surface of immune cells called B cells and removes them from circulating blood. BRIUMVI is approved by the FDA for the treatment of relapsing forms of multiple sclerosis in adults, which include clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS.
For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.
What it treats
Relapsing forms of Multiple Sclerosis (MS)
Prescribed by
Neurologists
How it’s administered
Intravenous (IV) infusion
Frequency
Second infusion two weeks after first infusion,
third infusion 24 weeks after first infusion & subsequent infusions every 24 weeks
Length of treatment
First infusion about four hours, subsequent infusions about one hour